| Study period | |||||
---|---|---|---|---|---|---|
Baseline | Allocation | Treatment | Follow-up phase | |||
Visit | Â | 1 | 2 | 3 | 4 | 5 |
Timepoint (week) | − 4 | 0 | 1–4 | 5–8 | 9–12 | 13–16 |
Enrolment: | ||||||
 Eligibility screen | X | X |  |  |  |  |
 Informed consent |  | X |  |  |  |  |
 Demographic characteristics |  | X |  |  |  |  |
 Treatment history |  | X |  |  |  |  |
 Combined diseases and medication |  | X | X | X | X | X |
 Information of migraine |  | X | X | X | X | X |
 Randomization |  | X |  |  |  |  |
 Allocation |  | X |  |  |  |  |
Interventions: | ||||||
 Manual acupuncture |  |  | X |  |  |  |
 Placebo acupuncture |  |  | X |  |  |  |
Assessments: | ||||||
 Headache diary |  | X | X | X | X | X |
 Visual analog scale |  | X | X | X | X | X |
 Migraine-specific Quality-of-Life Questionnaire Life Questionnaire (MSQ) |  | X | X | X | X | X |
 Headache impact test-6 (HIT-6) |  | X | X | X | X | X |
 Acupuncture Expectancy Questionnaire |  | X |  |  |  |  |
 Neuropeptide calcitonin gene-related peptide (CGRP) |  | X | X |  |  | X |
 Blinding for group allocation |  |  |  |  |  | X |
 Safety assessment |  | X | X | X | X | X |